All patients
HER2 negative Postmenopausal status
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
breast cancer - HR positive, phosphoinositide 3-kinase (PI3K) inhibitor vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results BELLE-2 (full population), 2017 0.87 [0.74; 1.02]
BELLE-2 (patients with known PI3K status), 2017 0.91 [0.75; 1.10]
SOLAR-1 (patients with PIK3CA mutant status), 2019 0.86 [0.64; 1.15]
0.88 [0.79 ; 0.99 ] BELLE-2 (full population), 2017, BELLE-2 (patients with known PI3K status), 2017, SOLAR-1 (patients with PIK3CA mutant status), 2019 3 0% 2,339 low not evaluable progression or deaths (PFS)detailed results BELLE-2 (full population), 2017 0.78 [0.68; 0.90]
BELLE-2 (patients with known PI3K status), 2017 0.80 [0.68; 0.94]
BELLE-2 (PI3K pathway activated), 2017 0.76 [0.60; 0.97]
SOLAR-1 (patients with PIK3CA mutant status), 2019 0.65 [0.50; 0.85]
SOLAR-1 (patients without PIK3CA mutant status), 2019 0.85 [0.58; 1.25]
0.77 [0.71 ; 0.84 ] BELLE-2 (full population), 2017, BELLE-2 (patients with known PI3K status), 2017, BELLE-2 (PI3K pathway activated), 2017, SOLAR-1 (patients with PIK3CA mutant status), 2019, SOLAR-1 (patients without PIK3CA mutant status), 2019 5 0% 2,942 low not evaluable CBRdetailed results SOLAR-1 (patients with PIK3CA mutant status), 2019 1.93 [1.25; 2.97]
1.93 [1.25 ; 2.97 ] SOLAR-1 (patients with PIK3CA mutant status), 2019 1 0% 341 NA not evaluable objective responses (ORR)detailed results BELLE-2 (full population), 2017 1.60 [1.08; 2.39]
BELLE-2 (patients with known PI3K status), 2017 1.47 [0.92; 2.34]
BELLE-2 (PI3K pathway activated), 2017 1.34 [0.66; 2.71]
LORELEI, 2019 1.55 [1.00; 2.39]
SOLAR-1 (patients with PIK3CA mutant status), 2019 2.47 [1.41; 4.34]
1.63 [1.32 ; 2.03 ] BELLE-2 (full population), 2017, BELLE-2 (patients with known PI3K status), 2017, BELLE-2 (PI3K pathway activated), 2017, LORELEI, 2019, SOLAR-1 (patients with PIK3CA mutant status), 2019 5 0% 3,045 low not evaluable pCR detailed results LORELEI, 2019 3.07 [0.32; 29.65]
3.07 [0.32 ; 29.65 ] LORELEI, 2019 1 0% 334 NA not evaluable 0.5 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-06-01 16:16 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 4,319,144,356,351,357,352,354,353,358,359
- treatments: 436,1409,717,1410,1418,1430,1360,1431,433,451,450,1377,1408,1378
